Going viral: a review of replication-selective oncolytic adenoviruses

Christopher Larson; Bryan Oronsky; Jan Scicinski; Gary R. Fanger; Meaghan Stirn; Arnold Oronsky; Tony R. Reid

doi:10.18632/oncotarget.5116

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Going viral: a review of replication-selective oncolytic adenoviruses

Christopher Larson, Bryan Oronsky _, Jan Scicinski, Gary R. Fanger, Meaghan Stirn, Arnold Oronsky and Tony R. Reid

PDF | HTML | How to cite

Oncotarget. 2015; 6:19976-19989. https://doi.org/10.18632/oncotarget.5116

Metrics: PDF 3200 views | HTML 5940 views | ?

Abstract

Christopher Larson1, Bryan Oronsky2, Jan Scicinski2, Gary R. Fanger2, Meaghan Stirn1, Arnold Oronsky3 and Tony R. Reid1

1 University of California at San Diego (UCSD), Moores Cancer Center, La Jolla, CA, USA

2 EpicentRx, Inc., Mountain View, CA, USA

3 InterWest Partners, Menlo Park, CA, USA

Correspondence to:

Bryan Oronsky, email:

Keywords: oncology, immunotherapy, oncolytic virus, adenovirus

Received: May 15, 2015 Accepted: July 09, 2015 Published: August 07, 2015

Abstract

Oncolytic viruses have had a tumultuous course, from the initial anecdotal reports of patients having antineoplastic effects after natural viral infections a century ago to the development of current cutting-edge therapies in clinical trials. Adenoviruses have long been the workhorse of virotherapy, and we review both the scientific and the not-so-scientific forces that have shaped the development of these therapeutics from wild-type viral pathogens, turning an old foe into a new friend. After a brief review of the mechanics of viral replication and how it has been modified to engineer tumor selectivity, we give particular attention to ONYX-015, the forerunner of virotherapy with extensive clinical testing that pioneered the field. The findings from those as well as other oncolytic trials have shaped how we now view these viruses, which our immune system has evolved to vigorously attack, as promising immunotherapy agents.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5116

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Going viral: a review of replication-selective oncolytic adenoviruses

Abstract